This Article Full Text (PDF) All Versions of this Article: 0962280207081860v1 17/5/487    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hughes, M. D Search for Related Content PubMed PubMed Citation Articles by Hughes, M. D Social Bookmarking                         What's this?

Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer

Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA, USA, mhughes{at}hsph.harvard.edu

This paper is based on a conference presentation in which several authors presented results from analyses of the same dataset concerning the evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival in advanced colorectal cancer clinical trials. In evaluating a potential surrogate endpoint, there is a hierarchy of information that might usually be considered desirable: 1) a biological rationale for surrogacy, 2) demonstration of the prognostic value of the surrogate endpoint in untreated patients and 3) in treated patients and 4) demonstration across randomized comparisons that differences in the effect of randomized treatments on the surrogate endpoint are associated with the corresponding differences in the effect on the clinical endpoint of interest. Results from analyses that might be used to address the third and four requirements are presented and some of the practical issues that arise in evaluating a surrogate endpoint, which would be relevant to many diseases, are illustrated. Although the results presented should not be seen as a definitive analysis of the value of PFS as a surrogate endpoint, concerns are identified about the potential lack of standardization of the definition of PFS or the frequency of evaluation of disease progression and the high leverage of one study in evaluating the association in addressing the fourth requirement.

This version was published on October 1, 2008

Statistical Methods in Medical Research, Vol. 17, No. 5, 487-495 (2008)
DOI: 10.1177/0962280207081860


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Piedbois and J. Miller Croswell Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective Statistical Methods in Medical Research, October 1, 2008; 17(5): 519 - 527. [Abstract] [PDF]